CYLD Antikörper
-
- Target Alle CYLD Antikörper anzeigen
- CYLD (Cylindromatosis (Turban Tumor Syndrome) (CYLD))
-
Reaktivität
- Human, Maus, Ratte
-
Wirt
- Kaninchen
-
Klonalität
- Polyklonal
-
Konjugat
- Dieser CYLD Antikörper ist unkonjugiert
-
Applikation
- ELISA, Immunohistochemistry (IHC)
- Aufreinigung
- Affinity purification
- Immunogen
- Synthetic peptide of human CYLD
- Isotyp
- IgG
- Top Product
- Discover our top product CYLD Primärantikörper
-
anti-Cylindromatosis (Turban Tumor Syndrome) (CYLD) (AA 170-338) antibody
CYLD Reaktivität: Human WB, IHC, IP, ICC Wirt: Kaninchen Polyclonal unconjugated
anti-Cylindromatosis (Turban Tumor Syndrome) (CYLD) (AA 654-953) antibodyCYLD Reaktivität: Human WB, IHC Wirt: Kaninchen Polyclonal unconjugated
anti-Cylindromatosis (Turban Tumor Syndrome) (CYLD) (C-Term) antibodyCYLD Reaktivität: Human, Maus WB, ICC, IF, IHC (p) Wirt: Kaninchen Polyclonal unconjugated
anti-Cylindromatosis (Turban Tumor Syndrome) (CYLD) (AA 204-358) antibodyCYLD Reaktivität: Human WB, ELISA, FACS Wirt: Maus Monoclonal 5F7F4 unconjugated
anti-Cylindromatosis (Turban Tumor Syndrome) (CYLD) (AA 269-435), (C-Term) antibodyCYLD Reaktivität: Human ELISA, IHC, IF Wirt: Kaninchen Polyclonal unconjugated
anti-Cylindromatosis (Turban Tumor Syndrome) (CYLD) (pSer418) antibodyCYLD Reaktivität: Human, Maus WB, ELISA, IHC (p) Wirt: Kaninchen Polyclonal unconjugated
anti-Cylindromatosis (Turban Tumor Syndrome) (CYLD) (AA 32-45) antibodyCYLD Reaktivität: Human, Maus, Rind (Kuh), Hamster, Affe, Huhn, Hund, Meerschweinchen, Pferd, Kaninchen WB, ICC Wirt: Kaninchen Polyclonal unconjugated
anti-Cylindromatosis (Turban Tumor Syndrome) (CYLD) (AA 305-582) antibodyCYLD Reaktivität: Human WB, FACS Wirt: Maus Monoclonal 1667CT857-3-6-1 unconjugated
anti-Cylindromatosis (Turban Tumor Syndrome) (CYLD) antibodyCYLD Reaktivität: Human, Maus, Ratte ELISA, IHC Wirt: Kaninchen Polyclonal unconjugated
anti-Cylindromatosis (Turban Tumor Syndrome) (CYLD) (AA 854-953) antibodyCYLD Reaktivität: Human ELISA, IF Wirt: Maus Monoclonal 2C3 unconjugated
-
- Applikationshinweise
- IHC 1:50-1:200
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Format
- Liquid
- Konzentration
- 0.7 mg/mL
- Buffer
- PBS with 0.05 % sodium azide and 50 % glycerol, PH7.4
- Konservierungsmittel
- Sodium azide
- Handhabung
- Avoid freeze / thaw cycles.
- Lagerung
- -20 °C
- Informationen zur Lagerung
- Store at -20°C. Avoid freeze / thaw cycles.
-
- Target
- CYLD (Cylindromatosis (Turban Tumor Syndrome) (CYLD))
- Andere Bezeichnung
- CYLD (CYLD Produkte)
- Synonyme
- BRSS antikoerper, CDMT antikoerper, CYLD1 antikoerper, CYLDI antikoerper, EAC antikoerper, MFT antikoerper, MFT1 antikoerper, SBS antikoerper, TEM antikoerper, USPL2 antikoerper, 2010013M14Rik antikoerper, 2900009M21Rik antikoerper, C130039D01Rik antikoerper, mKIAA0849 antikoerper, cyld antikoerper, LRRGT00003 antikoerper, Rp1 antikoerper, Rp1h antikoerper, CYLD lysine 63 deubiquitinase antikoerper, cylindromatosis (turban tumor syndrome), a antikoerper, CYLD antikoerper, Cyld antikoerper, cylda antikoerper
- Hintergrund
- This gene is encodes a cytoplasmic protein with three cytoskeletal-associated protein-glycine-conserved (CAP-GLY) domains that functions as a deubiquitinating enzyme. Mutations in this gene have been associated with cylindromatosis, multiple familial trichoepithelioma, and Brooke-Spiegler syndrome. Alternate transcriptional splice variants, encoding different isoforms, have been characterized.
- NCBI Accession
- NP_056062
- Pathways
- Apoptose, Activation of Innate immune Response
-
